Pesquisadores da USC identificam compostos que combatem a inflamação cerebral do Alzheimer

Cientistas da University of Southern California descobriram compostos experimentais que podem reduzir a inflamação cerebral prejudicial associada à doença de Alzheimer. O trabalho concentra-se na enzima cPLA2 e em pessoas portadoras do gene APOE4 de alto risco.

Pesquisadores da University of Southern California identificaram compostos que inibem seletivamente a cPLA2, uma enzima ligada à inflamação no cérebro. As descobertas foram publicadas na revista npj Drug Discovery em 2026. A equipe associou uma maior atividade da cPLA2 a um risco maior de Alzheimer entre portadores do gene APOE4, embora a enzima também suporte a função cerebral normal.

Artigos relacionados

Microscopic illustration of protective microglia clearing amyloid plaques in an Alzheimer's brain model due to the OLE molecule
Imagem gerada por IA

Study identifies OLE molecule that shifts microglia into a more protective state in Alzheimer’s models

Reportado por IA Imagem gerada por IA Verificado

Researchers in Spain and Switzerland report that an experimental molecule called OLE helped restore protective behavior in the brain’s immune cells in animal models of Alzheimer’s disease, reducing amyloid-related pathology and improving performance on memory and movement tests.

Researchers at the Indiana University School of Medicine have identified the enzyme IDOL as a potential new target for treating Alzheimer's disease. Laboratory studies showed that removing the enzyme from neurons reduced amyloid plaques and improved brain cell communication.

Reportado por IA

A major analysis of genetic data has linked 127 gene locations to Alzheimer’s disease, including 48 previously unidentified ones. Researchers also flagged several genes as promising drug targets and highlighted changes in immune and nerve cells.

Researchers at the University of Kentucky report that overactive microglia—immune cells in the brain—can drive sleep loss in mice with amyloid plaques. In the study, temporarily depleting most microglia restored more than two hours of sleep per day, even though plaque levels did not change.

Reportado por IA

A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.

Este site usa cookies

Usamos cookies para análise para melhorar nosso site. Leia nossa política de privacidade para mais informações.
Recusar